Top Picks: Accredited Activities

The Changing Face of Newly Diagnosed AML: Is There a Role for ISH Inhibitors?

The Changing Face of Newly Diagnosed AML: Is There a Role for ISH Inhibitors?

Daniel A. Pollyea, MD

The Role of HDAC Inhibition in the Frontline Setting

The Role of HDAC Inhibition in the Frontline Setting

Ehab Atallah, MD

Transplant as an Option for Patients with AML: Current Standard of Care

Transplant as an Option for Patients with AML: Current Standard of Care

Sergio A. Giralt, MD

Disclaimer

Testing Disclaimer

Most Viewed

ASH COVID-19 & AML: FAQs

ASH COVID-19 & AML: FAQs

AML thought leaders discuss challenges associated with treating your patients during the COVID-19 pandemic

Eytan M. Stein, MD

How to utilize and sequence new drugs in the treatment of AML

Eytan M. Stein, MD

Daniel A. Pollyea, MD

What education instruction are you providing to your patients with AML who are already immunocompromised and are you continuing treatment as planned?

Daniel A. Pollyea, MD

Recent Activities by Topic

Treatment

  • VIDEO FAQ: Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML - N. Daver, MD (6:03) - Posted 04/22
    video
  • VIDEO FAQ: In this setting of the COVID-19 pandemic, will clinical trials continue to enroll patients? - D. Pollyea, MD (1:59) - Posted 04/08
    video
  • VIDEO FAQ: What are the advantages and disadvantages of the different FLT3 inhibitors? - A. Perl, MD(1:57) - Posted 04/01
    video
  • e-NEWSLETTER: Evolving Treatment Paradigms in AML: New Data and Clinical Trials That Could Change Clinical Practice - N. Daver, MD - Posted 02/17
    text
  • Additional activities...

Diagnosis

  • PODCAST: What are the most important prognostic factors to consider in AML? - P. Desai, MD (2:19) - Posted 12/05
    podcast
  • VIDEO FAQ: How likely is it for patients with MDS to transform to AML? - J. Park, MD (3:33) - Posted 11/07
    video
  • VIDEO FAQ: What are the practical issues in FLT3 testing as it relates to PCR vs. NGS? - A. Perl, MD (3:18) - Posted 10/10
    video
  • VIDEO FAQ: What are the latest guidelines for molecular testing in AML? - J. Patel, MD (1:56) - Posted 07/24
    video
  • Additional activities...

Supporters

MediCom Worldwide, Inc. would like to recognize and thank the following companies for their educational support of Managing AML.com in 2018-2019

  • Agios Pharmaceuticals, Inc.
  • Celgene Corporation
  • Daiichi Sankyo, Inc.
  • Helsinn Healthcare SA
  • Jazz Pharmaceuticals
  • Pfizer Inc.

MediCom Oncology Links

Please visit these other members of the MediCom Oncology family of sites.

Managing MDS Managing Myeloma The Practical Oncologist
Managing Lymphoma Partners in Pancreatic Cancer Emerging Solutions in Pain